Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Boston Scientific executive Vance R. Brown, EVP, GC and Corporate Secretary, reported equity compensation changes tied to restricted stock units and options. On February 12, 2026, 1,442 restricted stock units were exercised into 1,442 shares of common stock, and 488 shares were disposed of to cover tax withholding at $74.12 per share.
Following these transactions, Brown directly held 34,405 shares of common stock. He also received new grants of 7,420 restricted stock units and 17,510 stock options with a $74.12 exercise price, each vesting in four equal annual installments beginning February 12, 2027.
Boston Scientific Corporation provides an overview of its global medical device business, strategy and key transactions in its annual report for the year ended December 31, 2025. The company highlights a definitive agreement to acquire Penumbra for $14.500 billion, funded with approximately $11.000 billion of cash and new debt and the balance in stock.
Boston Scientific reports an aggregate market value of common stock held by non‑affiliates of about $158.7 billion based on a $107.41 share price on June 30, 2025, and 1,483,885,456 shares outstanding as of January 30, 2026. Total debt was $11.436 billion as of December 31, 2025. The company employed roughly 59,000 people worldwide at year‑end 2025, with 36 percent of net sales generated outside the U.S.
The report details two completed 2025 acquisitions—Bolt Medical and SoniVie—to expand intravascular and hypertension technologies, and explains a 2023 restructuring program expected to generate annual pre‑tax savings of $350 million to $400 million from total charges of $700 million to $800 million. Extensive risk disclosures cover competition, pricing pressure, regulation, cybersecurity, supply chain, climate and human‑capital challenges.
Boston Scientific Corporation disclosed that director Yoshiaki Fujimori has informed the company he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.
Mr. Fujimori will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision is not due to any disagreement with the company. The Board and its Nominating and Governance Committee will continue reviewing Board size and composition and may consider adding directors after his departure.
Boston Scientific used its Q4 2025 call to highlight strong growth and the pending acquisition of Penumbra. The Cardiovascular segment grew 16% operationally and organically in the quarter and 21% organic for the full year, reflecting strength in fast-growing markets.
As of December 31, 2025, the company reported cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9x. All three major rating agencies affirmed its single A minus equivalent credit rating, and Fitch raised its outlook from stable to positive.
Management closed the acquisition of Nalu Medical and announced deals for Valencia Technologies and Penumbra, expanding into urology and neurovascular/mechanical thrombectomy adjacencies. The CEO reaffirmed long-range goals for 10%+ organic revenue growth from 2026–2028, about 150 bps margin expansion, and strong double-digit EPS growth, while cautioning that these are forward-looking statements subject to significant risks.
Boston Scientific Corporation furnished a Form 8-K to announce it issued a press release with financial results for the fourth quarter and full year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and is furnished rather than filed for liability purposes.
Boston Scientific’s Chairman, President & CEO Michael F. Mahoney reported routine equity transactions in company stock. On February 2, 2026, he exercised stock options for 49,407 shares at $24.55 and 46,347 shares at $27.09, converting them into common stock.
That same day, he sold 1,200 shares at a weighted average price of $94.0567 and 159,701 shares at a weighted average price of $93.4905. The filing states these trades were made under a pre-established Rule 10b5‑1 trading plan adopted on August 29, 2025.
After these transactions, Mahoney directly owned 1,411,735 Boston Scientific common shares and had stock options for 231,739 and 98,814 shares from prior grants. He also indirectly held 213,679 shares through a trust.
A shareholder of BSX filed a notice of proposed sale of 160,901 shares of common stock, with an aggregate market value of $15,043,390.17. The planned sales are to be executed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 02/02/2026.
The shares to be sold were acquired through a mix of performance shares, restricted stock, and a stock option exercise, all obtained directly from the issuer between 2018 and 2026, with the stock option portion paid in cash.
Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock deal valued at $14.5 billion. The company plans to fund about 73% of the price in cash and 27% in stock, and expects the transaction to close sometime this year, subject to conditions such as regulatory approvals.
The acquisition is intended to rebuild Boston Scientific’s neurovascular portfolio, adding devices that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs, and to complement its existing cardiovascular and brain-related businesses. Penumbra expects roughly $1.4 billion in 2025 revenue, growing more than 17% compared with 2024. Boston Scientific anticipates the deal will slightly dilute earnings in the first full year after closing, become neutral to slightly beneficial in the second year, and more beneficial thereafter, while potentially supporting its long-range goal of sustaining organic sales growth of 10% and higher.
Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at $14.5 billion. The company plans to fund about 73% of the deal in cash and 27% in stock, and expects the acquisition to close this year, subject to regulatory approvals and other conditions.
The transaction is designed to expand Boston Scientific’s cardiovascular portfolio and re-establish a strong neurovascular business, adding devices that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs. Penumbra expects roughly $1.4 billion of revenue in 2025, growing more than 17% over 2024. Boston Scientific anticipates the deal will slightly dilute profits in the first full year after closing, become neutral to slightly beneficial in the second year, and more beneficial thereafter.